A survey by PSG has found that the pressure to control drug costs is leading some payers to look into unbundling pharmacy ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

CVS Caremark identified GLP-1 drugs and Humira as points of contention, but the State Health Plan says that mischaracterizes ...

Some Blue Cross and Blue Shield insurers dipped their toes into expanding coverage for blockbuster weight-loss drugs, then ...

Fifteen Connecticut companies made the 2025 Fortune 500 list of the largest U.S. corporations, which was announced Monday-- a sign of stability in the state's corporate sector. Bloomfield- ...

While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future ...

The findings, published May 11… Eli Lilly’s weight loss drug Zepbound led to significantly ... issued in a sealed order by Judge Mark… CVS Caremark has selected Novo Nordisk’s Wegovy ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.